𝛼SK or Searchbullish
ECO Animal Health - FY26 trading update: adj. EBITDA materially ahead
SUMMARY
- - Revenue +8% YoY; FY26E raised to £86.0m (+3%) - North America lifted to £23.0m (+7% YoY); Latin America to £16.7m (+2%, reversing an 18% FY25 decline) - Gross margin nudged up to 45.5% on better pricing and input costs - Adj. EBITDA "materially ahead" of expectations; raised to £8.2m (12% YoY growth, 9.5% margin) - Forecasts raised across all three years - ECOVAXXIN® MS commercial launch across key European markets in 2026/27; peak revenue potential £22.2m - ECOVAXXIN® MG also in pipeline; peak revenue potential ~£10m - Fair Value raised to 180p/share - FY27 EV/EBITDA of 5.1x vs peer average of 13.5x
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- ECO Animal Health - FY26 trading update: adj. EBITDA materially ahead19 Mar 2026
x